22 Aug
2018
08:00 E.S.T.

Calyxt Names Biotech Veteran and Board of Directors Member Dr. Yves J. Ribeill as Interim CEO

Read more

02 Aug
2018
16:30 E.S.T.

Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer

Read more

01 Aug
2018
16:30 E.S.T.

Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018

Read more

27 Jun
2018
16:30 E.S.T.

Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018

Read more

12 Jun
2018
16:30 E.S.T.

Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports

Read more

08 Jun
2018
17:45 E.S.T.

Shareholders’ General Meeting of June 26, 2018

Read more

04 Jun
2018
16:30 E.S.T.

FDA Grants Cellectis IND Approval for UCART22 in B-ALL

Read more

22 May
2018
19:15 E.S.T.

Approval of UCART123 Amendment in AML to Accelerate Clinical Development

Read more

22 May
2018
16:00 E.S.T.

Calyxt Announces Successful Closing of $60.9 Million Public Offering

Read more

21 May
2018
08:30 E.S.T.

Calyxt Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

Read more